First patient dosed in Phase 3 SOLAIRIA program of GB-0895 in severe asthma

Generate Biomedicines/GB-0895 (anti-TSLP)

Generate Biomedicines dosed the first patient in Phase 3 SOLAIRIA on January 26, 2026. GB-0895 is an AI-designed antibody blocking TSLP, a protein that drives airway inflammation in severe asthma. The trial uses a convenient six-month dosing schedule achieved through engineering for extended half-life.

• GB-0895 is a long-acting monoclonal antibody targeting thymic stromal lymphopoietin (TSLP).
• Patients receive injections every six months (approximately 300 mg per dose).
• Full enrollment expected by the first half of 2028.
• Two parallel Phase 3 trials began in December 2025.